CLAY B. SIEGALL has a Ph.D. in genetics which he obtained from George Washington University. He also has a Bachelor of Science, Zoology which he attained at the University of Maryland.

He is a co-founder of Seattle Genetics Company which he has built on a foundation of innovation, through drug development research processes with a firm resolve and motivation to help patients.

He is the company’s president, CEO and also the chairperson of the board. Dr. Siegall is a trained scientist and has put most of his efforts into cancer therapy.

Before co-founding Seattle Genetics, Dr. Siegall worked in the Bristol- Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. He also worked at the National Cancer Institute between 1988 and 1991.

During Dr. Siegall’s time at the helm, Seattle Genetics has acquired many necessary licenses for its ADC technology including GlaxoSmithKline, Genentech, Pfizer, and AbbVie which have created more than $350 million.

There are more than 20 ADCs in clinical development that currently use Seattle Genetics technology across internal and collaborator programs. He has also led Seattle genetics’ capital raising endeavors generating more than $1.2 billion through various funding initiatives including the company’s initial public offering in 2001.

Dr. Siegall led the company in obtaining the 2011 FDA approval of its initial ADC product ADCETRIS which is now a worldwide brand that has been approved by more than 60 countries in partnership with Takeda pharmaceutical company.

Dr. Siegall is a member of the board of directors at Ultragenyx Pharmaceutical, Alder Biopharmaceuticals, and The Washington Roundtable. He has been the recipient of some accolades including the 2013 University of Maryland Alumnus of the year for Computer, Math and Natural sciences and the 2012 Pacific Northwest Ernst and Young Entrepreneur of the year award.

He has written more than 65 publications and also holds more than ten patents. Dr. Siegal’s motivation stems from his past experiences. For instance, the unfortunate experience of losing a father at the early age of 24 due to cancer motivated him to specialize in cancer therapy and treatment.